Excitatory amino acid agonists and antagonists: Pharmacology and therapeutic applications

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 221-229

  Trist, D G ^a  

^a GSK   (Italy)

Author keywords

Co agonism; Glycine antagonists; Ionotropic receptors; NMDA antagonists; Pain; Stroke

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 5 IODOWILLARDIINE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7,8,9 TETRAHYDRO 5 NITROBENZ[G]INDOLE 2,3 DIONE 3 OXIME; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; CYCLOSERINE; DIZOCILPINE; EXCITATORY AMINO ACID; GAVESTINEL; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; ION CHANNEL; IONOTROPIC RECEPTOR; KAINIC ACID; KAINIC ACID RECEPTOR; KYNURENIC ACID; L 294486; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

BINDING SITE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CONFERENCE PAPER; DEGENERATIVE DISEASE; DEPRESSION; DRUG DEPENDENCE; EPILEPSY; HUMAN; NEUROTRANSMISSION; PARKINSON DISEASE; RECEPTOR BINDING; SCHIZOPHRENIA; STROKE;

ANIMALS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0034025767     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00053-9     Document Type: Conference Paper

References (73)

1. Albers G.W., Saenz R.E., Moses J.A., Choi D.W. Safety and tolerance of oral Dextromethorpan in patients at risk for brain ischemia. Stroke. 22:1991;1075-1077.
2. Altamura C., Maes M., Dai J., Meltzer H.Y. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychopharmacol. 5:1995;71-75.
3. Andine P., Sandberg M., Bagenholm R., Lehmann A., Hagberg H. Intra- and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic-ischemia. Dev. Brain Res. 64:1991;115-120.
4. Barnard E.A. Ionotropic glutamate receptors: new types and new concepts. TIPS. 18:1997;141-148.
5. Bordi F., Pietra C., Ziviani L., Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp. Neurol. 145:1997;425-433.
6. Brauner-Osborne H., Nielsen B., Stensbol T.B., Johansen T.N., Skjaerbaek N., Krogsgaard-Larsen P. Molecular pharmacology of 4-substituted glutamic acid analogues at ionotropic and metabotropic excitatory amino acid receptors. Eur. J. Pharmacol. 335:1997;R1-R3.
7. Brose N., Gasic G.P., Vetter D.E., Sullivan J.M., Heinemann S.F. Protein chemical characterisation and immunocytochemical localisation of the NMDA receptor subunit NMDA R1. J. Biol. Chem. 268:1993;22663-22671.
8. Carey R.J., Dai H.L., Krost M., Huston J.P. The NMDA receptor and cocaine: evidence that MK-801 can induce behavioral sensitization effects. Pharmacol. Biochem. Behav. 51:1995;901-908.
9. Carlsson M., Carlsson A. Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
10. Cascella N.G., Macciardi F., Cavallini C., Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia - an open-label study. J. Neural Transm. 95:1994;105-111.
11. Castillo J., Davalos A., Noya M. Progression of ischaemic stroke and excitotoxic amino acids. Lancet. 349:1997;79-83.
12. Chittajallin R., Braithwaite S.P., Clarke V.R.J., Henley J.M. Kainate receptors: subunits, synaptic localization and function. TIPS. 20:1999;26-35.
13. Choi D. Antagonizing excitotoxicity: a therapeutic strategy for stroke? Mt. Sinai J. Med. 65:1998;133-138.
14. Ciabarra A.M., Sullivan J.M., Gahn L.G., Pecht G., Heinemann S., Sevarino K.A. Cloning and characterisation of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J. Neurosci. 15:1995;6498-6508.
15. Clarke V.R.J., Ballyk B.A., Hoo K.H., Mandelzys A., Pellizzari A., Bath C.P., Thomas J., Sharpe E.F., Davies C.H., Ornstein P.L., Schoepp D.D., Kamboj R.K., Collingridge G.L., Lodge D., Bleakman D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature (London). 389:1997;599-603.
16. Conn P.J., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:1997;205-237.
17. Contreras P.C. D-Serine antagonized phencyclidine-induced and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology. 29:1990;291-293.
18. Corsi M., Fina P., Trist D.G. Co-agonism in drug-receptor interaction: illustrated by the NMDA receptors. TIPS. 17:1996;220-222.
19. Czuczwar S.J., Meldrum B.S. Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur. J. Pharmacol. 83:1982;335-338.
20. Dansysz W., Parsons C.G. Glycine, NMDA receptors - physiological significance and possible therapeutic applications. Pharmacological Reviews. 50:1998;597-664.
21. Davar G., Hama A., Deykin A., Vos B., Maciewicz R. MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res. 553:1991;327-330.
22. Davies C.H., Clarke V.R.J., Jane D.E., Collingridge G.L. Pharmacology of postsynaptic metabotropic glutamate receptors in rat hippocampal CA1 pyramidal neurons. Br. J. Pharmacol. 116:1995;1859-1869.
23. Davis S.M., Albers G.W., Diener H.-C., Lees K.R., Norris J. Termination of acute stroke studies involving selfotel treatment. Lancet. 349:1997;32.
24. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacological Reviews. 51:1999;7-61.
25. Dougherty P.M., Willis W.D. Modification of the responses of primate spinothalamic neurons to mechanical stimulation by excitatory amino acids and an N-methyl-D-aspartate antagonist. Brain Res. 542:1991;15-22. Suppl. 1.
26. + conduction and selectivity. Science (Washington, D. C.). 280:1998;69-77.
27. Eide K., Stubhaug A., Oye I., Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain. 61:1995;221-228.
28. Eisenberg E., Pud D. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine? Pain. 74:1998;337-339.
29. Fadda E.D.W., Wroblewski J.T., Costa E. Glycine and D-serine increase the affinity of the N-methyl-D-aspartate sensitive glutamate binding sites in rat brain synaptic membranes. Neuropharmacology. 27:1988;1183-1185.
30. Felsby S., Nielsen J., Arendt-Nielsen L., Jensen T.S. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain. 64:1996;283-291.
31. Gereau R.W., Conn P.J. Roles of specific metabotropic glutamate receptor subtypes in regulation of hippocampal CA1 pyramidal cell excitability. J. Neurophysiol. 74:1995;122-129.
32. Globus M.Y.T., Busto R., Martinez E., Valdes I., Dietrich W.D., Ginsberg M.D. Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat. J. Neurochem. 57:1991;470-478.
33. Globus M.Y.T., Ginsberg M.D., Busto R. Excitotoxic index - a biochemical marker of selective vulnerability. Neurosci. Lett. 127:1991;39-42.
34. Green J.G., Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48:1996;613-634.
35. Greenamyre J.Y., Young A.B. Excitatory amino acids and Alzheimer's disease. Neurobiol. Aging. 10:1989;593-602.
36. Haley J.E., Sullivan A.F., Dickenson A.H. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res. 518:1990;218-226.
37. Herman B.H., Vocci F., Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal - medication development issues for opiate addiction. Neuropsychopharmacology. 13:1995;269-293.
38. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
39. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science. 214:1988;843-848.
40. Kupsch A., Loschmann P.-A., Sauer H., Arnold G., Renner P., Pufal D., Burg M., Wavhtel H., Ten Bruggencate G., Oertel W.H. Do NMDA receptor antagonists protect against MPIP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 181:1992;1-10.
41. Laube B., Hirozaku H., Sturgess M., Betz H., Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron. 18:1997;493-503.
42. Laube B., Kushe J., Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci. 18:1998;2954-2961.
43. Löscher W., Honack D. Effects of the competitive NMDA receptor antagonist, CGP-37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats. Eur. J. Pharmacol. 234:1993;237-245.
44. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical findings. Epilepsy Res. 2:1988;145-181.
45. Löscher W., Wlaz P., Rundfeldt C., Baran H., Honack D. Anticonvulsant effects of the glycine/NMDA receptor ligands d-cycloserine and d-serine but not R(+)-HA-966 in amygdala-kindled rats. Br. J. Pharmacol. 112:1994;97-106.
46. Mano I., Teichberg V.I. A tetrameric subunit stoichiometry for a glutamate receptor-channel complex. NeuroReport. 9:1998;327-331.
47. Marek P., Beneliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonist (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
48. Meldrum B.S., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. TIPS. 11:1990;379-387.
49. Mohr E., Knott V., Sampson M., Wesnes K., Herting R., Mendis T. Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clin. Neuropharmacol. 18:1995;28-38.
50. Monahan J.B., Hanadelmann G.E., Hood W.F., Cordi A.A. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol. Biochem. Behav. 34:1989;647-653.
51. Morrow B.A., Taylor J.R., Roth R.H. R-(+)-HA-966, an antagonist for the glycine NMDA receptor, prevents locomotor sensitization to repeated cocaine exposures. Brain Res. 673:1995;165-169.
52. Nakanishi N., Shneider N.A., Axel R. A family of glutamate receptor genes - evidence for the formation of heteromultimeric receptors with distinct channel properties. Neuron. 5:1990;569-582.
53. Nguyen L., Monaghan D.T., Cotman C.W. Glycine binding sites reciprocally interact with glutamate binding sites at NMDA receptor complex. Soc. Neurosci. Abstr. 13:1987;209.16.
54. Nowak G., Trullas R., Layer R.T., Skolnick P., Paul I.A. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J. Pharmacol. Exp. Ther. 265:1993;1380-1386.
55. Palmer A.M., Marion D.W., Botscheller M.L., Bowen D.M., Dekosky S.T. Increased transmitter amino acid concentration in human ventricular CSF after brain trauma. NeuroReport. 6:1994;153-156.
56. Paul I.A., Layer R.T., Skolnick P., Nowak G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur. J. Pharmacol., Mol. Pharmacol. 247:1993;305-311.
57. Pud D., Eisenberg E., Spitzer A., Adler R., Fried G., Yarnitsky D. NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain. 75:1998;349-354.
58. Quartaroli M., Carignani C., Dal Forno G., Mugnaini M., Ugolini A., Arban R., Bettelini L., Maraia G., Belardetti F., Reggiani A., Trist D.G., Ratti E., Di Fabio R., Corsi M. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A. J. Pharmacol. Exp. Ther. 290:1999;158-169.
59. Ren K., Hylden J.L.K., Williams G., Ruda M.A., Dubner R. The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioural hyperalgesia in rats. Eur. J. Pharmacol. 219:1992;235-243.
60. Rosenmund C., Stern-Bach Y., Stevens C.F. The tetrameric structure of a glutamate receptor channel. Science (Washington, D. C.). 280:1998;1596-1599.
61. Rosse R.B., Theut S.K., Banay-Schwartz M., Leighton M., Scarcella E., Cohen C.G., Deutsch S.I. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin. Neuropharmacol. 12:1989;416-424.
62. Schuster G.M., Schmidt W.J. D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. Eur. J. Pharmacol. 224:1992;97-98.
63. Simmons R.M.A., Li D.L., Hoo K.H., Deverill M., Ornstein P.L., Iyengar S. Kainate GluR5 receptor subtype mediates the nociceptive response to Formalin in the rat. Neuropharmacology. 37:1998;25-36.
64. Sirvio J., Ekonsalo T., Riekkinen P., Lahtinen H., Riekkinen P. D-cycloserine, a modulator of the N-methyl-D-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist. Neurosci. Lett. 146:1992;215-218.
65. Sluka K.A., Westlund K.N. An experimental arthritis in rats: dorsal horn aspartate, glutamate increases. Neurosci. Lett. 145:1992;141-144. Suppl. 2.
66. Sucher N.J., Awobuluyi M., Choi Y.B., Lipton S.A. NMDA receptors: from genes to channels. TIPS. 17:1996;348-355.
67. Swanson G.T., Green T., Heinemann S.F. Kainate receptors exhibit differential sensitivities to (S)-5-Iodowillardiine. Mol. Pharmacol. 53:1998;942-949.
68. Toth E., Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem. Int. 11:1986;393-400.
69. Turski L., Huth A., Sheardown M., McDonald F., Neuhaus R., Schneider H., Dirnagl U., Wiegand F., Jacobsen P., Ottow E. ZK20075: a phosphonate quinoxalinedione/(AMPA) antagonist for neuroprotection in stroke and trauma. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10960-10965.
70. Wahl P., Anker C., Traynelis S.F., Egebjerg J., Rasmussen J.S., Krosgaard-Larsen P., Madsen U. Antagonist properties of a phosphono isoxazole amino acid at glutamate R1-4 (R,S)-2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid receptor subtypes. Mol. Pharmacol. 53:1998;590-596.
71. Waziri R. Glycine therapy of schizophrenia. Biol. Psychiatry. 23:1988;209-214.
72. Williams K., Chao J., Kashiwagi K., Masuko T., Igarashi K. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit. Mol. Pharmacol. 50:1996;701-708.
73. Wong L.A., Mayer M.L., Jane D.E., Watkins J.C. Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons. J. Neurosci. 14:1994;3881-3897.